Mengxiong Wang

Mengxiong Wang

Auto-generated profile, based on publicly available information

Mengxiong Wang

Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MWMengxiong Wang
Mengxiong Wang
MLMary Law
Mary Law
RCRonald Castellano
Ronald Castellano
BLBrian K. Law
Brian K. Law

7 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
RFRenan B. Ferreira
Renan B. Ferreira
MWMengxiong Wang
Mengxiong Wang
MLMary E. Law
Mary E. Law
BDBradley J. Davis
Bradley J. Davis
ABAshton N. Bartley
Ashton N. Bartley
BLBrian K. Law
Brian K. Law
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells

10 December 2019 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
MWMengxiong Wang
Mengxiong Wang
MLMary E. Law
Mary E. Law
BDBradley J. Davis
Bradley J. Davis
EYElham Yaaghubi
Elham Yaaghubi
AGAmanda F. Ghilardi
Amanda F. Ghilardi
BLBrian K. Law
Brian K. Law
Disulfide bond-disrupting agents (DDAs) are a new chemical class of agents recently shown to have activity against breast tumors in animal models. Blockade of tumor growth is associated with downregulation of EGFR, HER2, and HER3 and reduced Akt phosphorylation, as well as the induction of endoplasmic reticulum stress. However, it is not known how DDAs trigger cancer cell death without affecting nontransformed cells. As demonstrated here, DDAs are the first compounds identified that upregulate the TRAIL receptor DR5 through transcriptional and post-transcriptional mechanisms to activate the extrinsic cell death pathway. At the protein level, DDAs alter DR5 disulfide bonding to increase steady-state DR5 levels and oligomerization, leading to downstream caspase 8 and 3 activation. DDAs and TRAIL synergize to kill cancer cells and are cytotoxic to HER2+ cancer cells with acquired resistance to the EGFR/HER2 tyrosine kinase inhibitor Lapatinib. Investigation of the mechanisms responsible for DDA selectivity for cancer cells reveals that DDA-induced upregulation of DR5 is enhanced in the context of EGFR overexpression. DDA-induced cytotoxicity is strongly amplified by MYC overexpression. This is consistent with the known potentiation of TRAIL-mediated cell death by MYC. Together, the results demonstrate selective DDA lethality against oncogene-transformed cells, DDA-mediated DR5 upregulation, and protein stabilization, and that DDAs have activity against drug-resistant cancer cells. Our results indicate that DDAs are unique in causing DR5 accumulation and oligomerization and inducing downstream caspase activation and cancer cell death through mechanisms involving altered DR5 disulfide bonding. DDAs thus represent a new therapeutic approach to cancer therapy.

4 February 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
MWMengxiong Wang
Mengxiong Wang
RFRenan B. Ferreira
Renan B. Ferreira
MLMary E. Law
Mary E. Law
BDBradley J. Davis
Bradley J. Davis
EYElham Yaaghubi
Elham Yaaghubi
BLBrian K. Law
Brian K. Law

19 March 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
MLMary E. Law
Mary E. Law
ZDZaafir M. Dulloo
Zaafir M. Dulloo
SESamantha R. Eggleston
Samantha R. Eggleston
Gregory TakacsGregory Takacs
Gregory Takacs
GAGrace M. Alexandrow
Grace M. Alexandrow
BLBrian K. Law
Brian K. Law
New agents are needed that selectively kill cancer cells without harming normal tissues. The TRAIL ligand and its receptors, DR5 and DR4, exhibit cancer-selective toxicity. TRAIL analogs or agonistic antibodies targeting these receptors are available but have not yet received FDA approval for cancer therapy. Small molecules for activating DR5 or DR4 independently of protein ligands may activate TRAIL receptors as a monotherapy or potentiate the efficacy of TRAIL analogs and agonistic antibodies. Previously described disulfide bond–disrupting agents activate DR5 by altering its disulfide bonding through inhibition of protein disulfide isomerases ERp44, AGR2, and PDIA1. Work presented in this article extends these findings by showing that disruption of single DR5 disulfide bonds causes high-level DR5 expression, disulfide-mediated clustering, and activation of caspase 8/caspase 3–mediated proapoptotic signaling. Recognition of the extracellular domain of DR5 by various antibodies is strongly influenced by the pattern of DR5 disulfide bonding, which has important implications for the use of agonistic DR5 antibodies for cancer therapy and as research tools. Importantly, other endoplasmic reticulum (ER) stressors, including thapsigargin and tunicamycin, also alter DR5 disulfide bonding in various cancer cell lines, and in some instances, DR5 mis-disulfide bonding is potentiated by overriding the integrated stress response (ISR) with inhibitors of the PERK kinase or the ISR inhibitor ISRIB. These observations indicate that the pattern of DR5 disulfide bonding functions as a sensor of ER stress and serves as an effector of proteotoxic stress by driving extrinsic apoptosis independently of extracellular ligands. Implications: Extreme ER stress triggers triage of transmembrane receptor production, whereby mitogenic receptors are downregulated and death receptors are simultaneously elevated.

21 October 2025 in Cancer Discovery
Verified
Journal Article
Open access
MWMengxiong Wang
Mengxiong Wang
KBKathryn T. Bieging-Rolett
Kathryn T. Bieging-Rolett
AKAlyssa M. Kaiser
Alyssa M. Kaiser
CBColleen A. Brady
Colleen A. Brady
JLJohn Lockhart
John Lockhart
LALaura D. Attardi
Laura D. Attardi
Pharmacologic restoration of p53 tumor suppressor function is a conceptually appealing therapeutic strategy for the many deadly cancers with compromised p53 activity, including lung adenocarcinoma. However, the p53 pathway has remained undruggable, partly because of insufficient understanding of how to drive effective therapeutic responses without toxicity. In this study, we use mouse and human models to deconstruct the transcriptional programs and sequelae underlying robust therapeutic responses in lung adenocarcinoma. We show that p53 drives potent tumor regression by direct Tsc2 transactivation, leading to mTORC1 inhibition and Transcription factor EB (TFEB) nuclear accumulation, which in turn triggers lysosomal gene expression programs, autophagy, and cellular senescence. Senescent lung adenocarcinoma cells secrete factors to recruit macrophages, precipitating cancer cell phagocytosis and tumor regression. Collectively, our analyses reveal a surprisingly complex cascade of events underlying a p53 therapeutic response in lung adenocarcinoma and illuminate targetable nodes for p53 combination therapies, thus establishing a critical framework for optimizing p53-based therapeutics. Significance: Cancer therapies based on targeting the p53 pathway remain elusive. To address this gap, we unravel the detailed sequence of events governing p53-induced tumor regression in lung adenocarcinoma. These analyses reveal a TSC2–mTORC1–TFEB axis underlying p53-driven senescence and tumor regression, which suggests new strategies to perfect p53-based combination therapies for lung adenocarcinoma.